申请人:Rigel Pharmaceuticals, Inc.
公开号:US20170158683A1
公开(公告)日:2017-06-08
Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.